Sinopharm Denies Ties to Human Remains Scandal

China National Medicines, a Sinopharm unit, refutes any business connections with Shanxi Osteorad Biomaterial Co., alleged in human remains scandal. The company confirmed these reports as incorrect and stated its operations are unaffected. Authorities have initiated an investigation into the claims.

China National Medicines, a subsidiary of Sinopharm, declared on Friday that it has no business relationships with Shanxi Osteorad Biomaterial Co. The announcement came through a filing to the Shanghai Stock Exchange.

According to government-backed media, The Paper, Shanxi Osteorad is under suspicion for illegally acquiring human remains to manufacture allogeneic bone implantable materials. The publication reported that local authorities have started an investigation into the alleged illegal theft and sales of thousands of bodies.

In its filing, China National Medicines dismissed media reports suggesting its involvement with Shanxi Osteorad as 'incorrect' and assured that its production and operations continue as usual. Shanxi Osteorad, which lacks an official website, was unavailable for comment.

(With inputs from agencies.)